GlassScriptPhysician profile
Eric Foster
NPI 1437634839
$16,624.11
in general payments reported to CMS, 2019-2025
35 companies · $3,694 in 2025
The $3,694 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,087 · 2022: $3,396 · 2023: $3,270 · 2024: $3,177 · 2025: $3,694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,140.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $6,099.80 | 2021-2025 | Cabenuva, Dovato, Apretude |
| Gilead Sciences, INC. | $4,391.03 | 2021-2025 | Biktarvy, Yeztugo |
| Merck Sharp & Dohme LLC | $1,069.65 | 2021-2025 | Pifeltro, Delstrigo, Capvaxive |
| Abbvie INC. | $1,035.77 | 2021-2025 | |
| Theratechnologies INC. | $900.81 | 2021-2025 | Egrifta, Trogarzo |
| Janssen Biotech, INC. | $771.57 | 2021-2023 | Symtuza |
| Emd Serono, INC. | $535.52 | 2021-2025 | Serostim |
| Napo Pharmaceuticals INC | $326.35 | 2021-2025 | Mytesi |
| Pfizer INC. | $211.08 | 2021-2024 | |
| Janssen Products, LP | $148.95 | 2021-2022 | |
| Lilly USA, LLC | $126.72 | 2023-2025 | Mounjaro, Zepbound |
| Antares Pharma, INC. | $115.21 | 2022-2023 | Nocdurna, Xyosted, Tlando |
| Paratek Pharmaceuticals, INC. | $110.05 | 2021-2024 | Nuzyra |
| Biohaven Pharmaceutical Holding Company LTD. | $99.11 | 2022 | |
| Axsome Therapeutics, INC. | $96.53 | 2023-2025 | Auvelity |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.70 | 2023-2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $57.46 | 2021-2023 | Livalo, Seglentis |
| Halozyme INC | $51.74 | 2023 | |
| Acerus Pharmaceuticals Corporation | $51.74 | 2021-2022 | |
| Hologic Sales and Service, LLC | $45.52 | 2023-2024 | Thinprep 2000 Processor, Aptima |
| Esperion Therapeutics, INC. | $40.90 | 2021 | |
| Baxter Healthcare | $35.35 | 2023 | Hillrom - Welch Allyn Macroview Plus |
| Glaxosmithkline, LLC. | $31.30 | 2021-2023 | Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $30.81 | 2021 | |
| Eisai INC. | $23.15 | 2021 | |
| Dynavax Technologies Corporation | $19.86 | 2021 | |
| Novo Nordisk INC | $19.67 | 2022 | |
| Nabriva Therapeutics, Plc | $19.55 | 2022 | |
| Neurocrine Biosciences, INC. | $18.87 | 2025 | |
| Tolmar, INC. | $15.93 | 2023 | |
| Hikma Pharmaceuticals USA | $14.28 | 2021 | |
| Eyevance Pharmaceuticals LLC | $14.28 | 2021 | |
| Janssen Scientific Affairs, LLC | $12.49 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $12.00 | 2022 | |
| Clarus Therapeutics INC. | $11.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Foster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.